{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-014142","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2026-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.707336+00:00","generated_at":"2026-05-16T10:17:48.244822+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"XOMA Royalty names Jeffrey Trigilio CFO; Thomas Burns departs after ~19 years","bullets":["Thomas Burns stepped down as CFO effective Jan 12, 2026; separation agreement includes $16k/month consulting for 3 months.","Jeffrey Trigilio appointed CFO effective Jan 12; was CFO/COO at Obsidian Therapeutics and CFO at Cullinan Therapeutics.","Trigilio receives $515k base salary, 40% target bonus, initial grant of 30,000 performance units, and annual equity grant in 2026.","Severance for Trigilio: 0.75x base salary, pro-rated bonus, 9-month health benefits; doubled to 1.5x base+bonus on change of control."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-014142","json":"https://secwatch.observer/filing/0001193125-26-014142.json","markdown":"https://secwatch.observer/filing/0001193125-26-014142.md","text":"https://secwatch.observer/filing/0001193125-26-014142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312526014142/0001193125-26-014142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312526014142/d59764d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:17:48.244822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}